Hudson Bay Capital Management’s Coherus Oncology CHRS Stock Holding History

Hudson Bay Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37M	Sell	1,693,000 -11,980	-0.7%	-$19.6K	0.01%	780
2026 Q1	$2.88M	Buy	1,704,980 +869,980	+104%	+$1.54M	0.01%	670
2025 Q4	$1.19M	Buy	835,000 +25,000	+3%	+$36.4K	﹤0.01%	779
2025 Q3	$1.33M	Sell	810,000 -25,000	-3%	-$27.8K	﹤0.01%	814
2025 Q2	$611K	Hold	835,000	–	–	﹤0.01%	1048
2025 Q1	$674K	Hold	835,000	–	–	﹤0.01%	987
2024 Q4	$1.15M	Buy	835,000 +50,000	+6%	+$56.1K	﹤0.01%	724
2024 Q3	$816K	Hold	785,000	–	–	﹤0.01%	695
2024 Q2	$1.36M	Buy	785,000 +85,000	+12%	+$171K	0.01%	575
2024 Q1	$1.67M	Buy	700,000 +115,000	+20%	+$283K	0.01%	485
2023 Q4	$1.95M	Buy	585,000 +175,000	+43%	+$469K	0.01%	461
2023 Q3	$1.53M	Sell	410,000 -27,500	-6%	-$127K	0.01%	517
2023 Q2	$1.87M	Buy	437,500 +287,500	+192%	+$1.7M	0.01%	516
2023 Q1	$1.03M	Hold	150,000	–	–	0.01%	587
2022 Q4	$1.19M	Buy	+150,000	New	+$1.15M	0.01%	672
2022 Q3	–	Sell	-155,000	Closed	-$1.12M	–	1240
2022 Q2	$1.12M	Buy	+155,000	New	+$1.35M	0.01%	904
2021 Q4	–	Sell	-30,000	Closed	-$482K	–	1101
2021 Q3	$482K	Sell	30,000 -55,000	-65%	-$806K	0.01%	824
2021 Q2	$1.18M	Sell	85,000 -7,500	-8%	-$106K	0.01%	707
2021 Q1	$1.35M	Buy	+92,500	New	+$1.57M	0.02%	639
2020 Q4	–	Sell	-45,000	Closed	-$825K	–	609
2020 Q3	$825K	Sell	45,000 -25,000	-36%	-$465K	0.01%	442
2020 Q2	$1.25M	Buy	70,000 +25,000	+56%	+$423K	0.02%	361
2020 Q1	$730K	Buy	45,000 +4,660	+12%	+$86.1K	0.02%	356
2019 Q4	$726K	Buy	+40,340	New	+$744K	0.02%	331
2019 Q1	–	Sell	-100,000	Closed	-$905K	–	712
2018 Q4	$905K	Buy	+100,000	New	+$1.16M	0.01%	648
2018 Q2	–	Sell	-23,035	Closed	-$255K	–	798
2018 Q1	$255K	Buy	+23,035	New	+$252K	0.01%	718
2015 Q4	–	Sell	-145,261	Closed	-$2.91M	–	190
2015 Q3	$2.91M	Buy	+145,261	New	+$4.42M	0.13%	101

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Hudson Bay Capital Management's CHRS Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Coherus Oncology (CHRS) stake by 0.7% in Q2 2026, selling an estimated $19.6K and leaving 1,693,000 shares worth $2.37M. The position accounts for 0.01% of the portfolio, ranked #780.

Hudson Bay Capital Management first reported a position in CHRS in Q3 2015 and has held it in 26 quarters since. The position peaked at $2.91M in Q3 2015. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Hudson Bay Capital Management held 1,693,000 shares of Coherus Oncology worth $2.37M as of Q2 2026.
Hudson Bay Capital Management sold 11,980 Coherus Oncology shares in Q2 2026, an estimated $19.6K.
Coherus Oncology made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #780 holding.
Hudson Bay Capital Management first reported a position in Coherus Oncology in Q3 2015 and has held it in 26 quarters since.
Hudson Bay Capital Management's Coherus Oncology position peaked at $2.91M in Q3 2015.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.